Cencora, Inc. $COR Position Reduced by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA trimmed its position in Cencora, Inc. (NYSE:COR) by 19.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 657,710 shares of the company’s stock after selling 159,854 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.34% of Cencora worth $205,554,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Security Financial Services INC. boosted its stake in Cencora by 2.6% in the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after purchasing an additional 33 shares during the period. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares in the last quarter. Hemington Wealth Management boosted its position in shares of Cencora by 12.0% in the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock worth $102,000 after buying an additional 35 shares during the period. Quadcap Wealth Management LLC raised its position in Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after buying an additional 36 shares during the period. Finally, U.S. Capital Wealth Advisors LLC raised its position in Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after buying an additional 38 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares in the company, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 15,220 shares of company stock valued at $5,343,561. Corporate insiders own 10.80% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $354.96 on Tuesday. The firm has a market cap of $68.86 billion, a price-to-earnings ratio of 44.65, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. The company’s fifty day moving average is $349.45 and its 200-day moving average is $320.73. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12 month low of $237.71 and a 12 month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. Cencora’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is currently 30.19%.

Analysts Set New Price Targets

Several equities analysts have weighed in on COR shares. Robert W. Baird set a $415.00 target price on Cencora in a research note on Tuesday, January 13th. TD Cowen boosted their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. UBS Group lifted their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $381.42.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.